HitGen(SH:688222) Zheng Quan Zhi Xing·2025-06-19 09:59Summary of Key Points Core Viewpoint - The announcement details the share reduction by the major shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., which has reduced its stake in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. by 2,000,000 shares, representing 0.50% of the total share capital. Group 1: Shareholder Background - Before the reduction plan, Huabo Medical held 46,770,579 shares, accounting for 11.67% of the total share capital, with these shares acquired prior to the company's IPO and released for trading on April 16, 2021 [1][2]. - Huabo Medical is identified as a direct shareholder holding more than 5% of the shares [2]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on March 3, 2025, with the intention to sell shares through centralized bidding from March 24, 2025, to June 23, 2025, with a limit of 1% of the total shares within any 90-day period [1]. - The actual reduction occurred between April 18, 2025, and June 19, 2025, with a total of 2,000,000 shares sold [2][4]. Group 3: Financial Details of the Reduction - The shares were sold at a price range of 14.66 to 17.79 yuan per share, resulting in a total reduction amount of 31,753,578.19 yuan [3]. - After the reduction, Huabo Medical holds 44,770,579 shares, which is 11.17% of the total share capital [3][4].